Akums Baddi Plant Targets 10%-15% of CDMO Sales in Three Years
Key highlights
- Akums plans roughly 12 billion annual oral-solid tablets of capacity at its phased Baddi facility.
- Baddi Phase 1, with more than 6 billion tablets of annual capacity, is expected to begin operating in the next three to four months.
- Management expects Baddi to contribute 10%-15% of CDMO business within three years.
- Akums' CDMO revenue rose 38.6% year on year to Rs 1,115 crore in the quarter ended September 30, 2026.
powered by IRIS

Akums Group expects its second Baddi plant to add roughly 12 billion oral-solid tablets through phased commissioning and contribute 10%-15% of its contract development and manufacturing organisation, or CDMO, business within three years. Phase 1, with annual capacity of more than 6 billion tablets, is expected to begin operating in the next three to four months.
Know Akums Drugs & Pharmaceuticals inside out
Results, valuation, peers and who's buying, in one view.
How large is Akums' Baddi expansion?
Akums plans roughly 12 billion tablets of annual oral-solid capacity from the Baddi facility across two phases. Management said Phase 1 will provide more than 6 billion tablets in various forms, on top of the company's existing annual capacity of roughly 50 billion to 51 billion units. A subsequent phase is intended to contribute another 6 billion-odd tablets.
The project includes more than a single oral-solid line because Akums is also planning other dosage forms within the Baddi facility. The call did not specify the capacity, investment or launch date for those additional forms, so the roughly 12 billion-unit figure applies to the stated oral-solid tablet phases rather than the entire eventual facility.
When will Akums' Baddi plant begin operations?
Akums said Baddi Phase 1 should be operational in the next three to four months, while the first-phase oral-solid capacity is expected to be fully operational by Q1 FY28. This distinguishes the initial start-up schedule from the point at which management expects the first phase to be fully operational.
The remaining phases have no disclosed completion schedule. Management said the facility would be operationalised gradually in three phases, although it described two additions of about 6 billion tablets each. The timing and scale of the third phase, as well as the planned extra dosage forms, remain undisclosed.
How much CDMO revenue could Akums' Baddi facility generate?
Akums said the Baddi facility should deliver 10%-15% of its CDMO business three years from now. This is management's contribution framework rather than formal company-wide revenue guidance, and it covers the facility as it is operationalised through three phases.
CDMO revenue was Rs 1,115 crore in the quarter ended September 30, 2026, up 38.6% year on year and 15.6% quarter on quarter. The call did not include a three-year CDMO sales forecast, so the stated 10%-15% range cannot be converted into a future rupee revenue amount.
The expansion follows four quarters in which management said CDMO volumes had grown by more than 20% year on year. Management attributed the volume increase to a mix of existing and new customers, including prescription-oriented, private-label and regional customers, with Baddi intended to add production capacity alongside that demand trend.
What has Akums disclosed about Baddi capex and funding?
Akums has not disclosed total capex for the Baddi facility, saying it would provide the figure as the plant matures. The company had invested around Rs 43 crore in Baddi during H1 FY27, while total H1 investment was Rs 210 crore, including the around Rs 56 crore Oriflame acquisition and investment in other facilities.
Management said historical annual capex had been close to Rs 300 crore and indicated spending could be somewhat higher while Baddi is operationalised and the acquired plant is developed. It cited a gross block of Rs 2,400 crore and said maintenance capex at 5% would put about Rs 100 crore into plants, alongside a small investment in Hana.
Funding has not been fixed. The chief financial officer said Akums could raise debt or use its own funds, depending on the relative cost of loans and liquidating investments. Cash and cash equivalents stood at Rs 1,680 crore on September 30, 2026, while H1 free cash flow was Rs 45.5 crore after a business acquisition.
Got a follow-up? Ask IRIS
How does Baddi fit Akums' current earnings mix?
Akums is directing the Baddi plan at CDMO, its largest disclosed revenue segment. In the September 2026 quarter, CDMO revenue of Rs 1,115 crore exceeded domestic branded formulations revenue of Rs 132 crore, international branded formulations revenue of Rs 44 crore, active pharmaceutical ingredients, or API, revenue of Rs 29 crore, and trade generics revenue of Rs 23 crore.
CDMO earnings also rose faster than group revenue in the reported quarter. Segment earnings before interest, tax, depreciation and amortisation, or EBITDA, were Rs 168 crore, up 99.6% year on year, while consolidated EBITDA was Rs 195 crore, up 106% and consolidated revenue rose 31.9% to Rs 1,342 crore.
Management said oral-solid businesses usually achieve revenue equal to three times gross block, but did not give a Baddi-specific gross-block amount or a timetable for reaching that turnover. The relationship was a management observation, not a Baddi revenue forecast.
What other commercial milestones could affect Akums' expansion plans?
Akums expects two external commercial programmes to begin contributing around FY28. For Zambia, it said purchase orders had been received and supplies were expected to be dispatched in Q4 FY27, but an estimated 100-120 day shipment from Haridwar to Lusaka means revenue is expected in Q1 FY28 rather than in the current year.
For Europe, Akums said its dossier had been filed and management believed regulatory approval could take one or two quarters. The supply plant is already approved, but purchase orders would follow dossier approval; management also said the European CDMO project remained on plan for supplies to start in FY28, with no European contract revenue included in H1 FY27 profit and loss.
Conclusion
Akums has set a measurable objective for Baddi: roughly 12 billion oral-solid tablets of phased annual capacity and 10%-15% of CDMO business within three years. The plan follows a September 2026 quarter in which CDMO revenue rose 38.6% year on year to Rs 1,115 crore and management reported volume growth above 20% for a fourth consecutive quarter.
The next disclosed milestones are Phase 1 beginning operations in the next three to four months, full Phase 1 operationalisation by Q1 FY28, and total Baddi capex disclosure as the facility matures. Management also expects Zambia revenue recognition in Q1 FY28 and indicated the pending European dossier approval could take one or two quarters.


